IN THIS ISSUE
Personalised medicine has been hailed as a game changer for the global pharma industry, bringing an end to the one-size-fits-all approach to medicine and introducing a new wave of customised treatments tailored to the needs of individual patients. We examine what needs to change as drugmakers transition from large batches to small and customised supplies.
We also explore the financial challenges of CAR-T cell therapies. Will nations around the world be able to afford the price tag attached to one of the industry’s most advanced – and expensive – therapies? Plus, we take a look at a new platform that uses AI to optimise drug combination therapy.
Finally, we find out more about the importance of the microbiome in personalised medicine. Could a better understanding of this community of bacteria, viruses and microorganisms supplant genetics as the primary target for precision medicine? All this plus the latest market and innovation insights from GlobalData.
Eloise McLennan, editor